(STTK) Shattuck Labs, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(STTK) Shattuck Labs, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Shattuck Labs, Inc. BCG Matrix helps you see how the company’s products or business units may be classified across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation analysis. The page already shows a real preview of the actual report content, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
No approved products
Shattuck Labs has 0 approved products and remained a clinical-stage biotech through end-2025, so it has no true commercial Star. Its value still depends on future trial wins, not on current market share or product sales. In FY2025, that means no approved-therapy revenue base to support a Star position.
SL-172154 lead asset
SL-172154 is Shattuck Labs, Inc.’s lead experimental compound and the clearest path to a future Star if data stay strong. It is still pre-commercial, so there is no product revenue yet, and R&D remains the main cash burn driver. That makes it high-upside but capital intensive, with value tied to clinical readouts and later partnering or approval.
SL-279252 second asset
SL-279252 is Shattuck Labs, Inc.'s other active pipeline asset, so it adds pipeline optionality and keeps the Star case alive. It still has no market share or revenue, and its value is tied almost fully to clinical progress; for FY2025, Shattuck Labs, Inc. reported no product sales, so this program remains a binary development bet.
2 active clinical programs
Shattuck Labs has only 2 active clinical programs, so its pipeline is still highly concentrated. That can create outsized upside if one asset delivers strong data, but it also means Shattuck Labs lacks the scale and diversification of a broad commercial engine.
- 2 shots on goal
- High binary upside
- Low pipeline diversification
2016 founded
Shattuck Labs, Inc., founded in 2016, is still a young biotech, so its profile fits pipeline development more than a true BCG Stars case. Young biotechs usually have no steady product cash flow yet, which means growth is tied to clinical progress, not market share from mature drugs. That makes this an early-stage asset, not a proven commercial star.
- Founded in 2016
- Development-stage, not mature
- Pipeline-driven value
Shattuck Labs: High-Risk, Pipeline-Driven Upside
Shattuck Labs, Inc. has no approved products in FY2025, so it has no true BCG Star yet. Its "Stars" case rests on 2 clinical assets, SL-172154 and SL-279252, but both are pre-revenue and depend on trial data. With 0 product sales and 100% pipeline-driven value, the upside is high but binary.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Active clinical programs | 2 |
| Product sales | 0 |
What is included in the product
Detailed Word Document
Shattuck Labs BCG Matrix: a concise view of pipeline assets by growth and market share, guiding invest, hold, or divest decisions.
Editable Excel File
Clean BCG Matrix for Shattuck Labs, Inc. that quickly spots growth priorities and portfolio gaps
Reference Sources
Shattuck Labs, Inc. Reference Sources provide a clear, traceable trail that boosts credibility and helps decision-makers verify key claims fast.
Cash Cows
0 approved therapies
Shattuck Labs has 0 approved therapies, so it has no product sales to create stable cash flow. Cash Cows need a mature commercial base and recurring revenue, which this Company does not have yet. In its latest fiscal reporting, the business is still R&D-driven, not a cash-generating commercial platform.
$0 product revenue
Shattuck Labs, Inc. has no product-sales franchise, so this is not a cash cow. With $0 product revenue, the business cannot self-fund operations from commercial milk; it must rely on cash on hand, equity raises, or debt until clinical data unlocks a real revenue stream.
No mature market share
Shattuck Labs, Inc. does not fit the Cash Cow box because both named programs are still in early development, so the company has no high-share, mature market to harvest. Its portfolio remains pre-commercial, with no marketed product revenue to support cash generation. In BCG terms, that means the asset base is still a build stage, not a cash engine.
Clinical R&D spend
Development-stage biotech companies spend cash on trials and research, so Clinical R&D spend is a cash use, not a Cash Cow. Shattuck Labs is still in investment mode because its pipeline needs clinical funding before it can generate steady operating cash flow. That fits a BCG Question Mark better than a Cash Cow.
- R&D supports trials, not cash harvest.
- Shattuck Labs remains pre-commercial.
- Cash burn is still the main story.
Austin, Texas headquarters
The Austin, Texas headquarters is a corporate base, not a Cash Cow: it does not produce recurring operating cash on its own. Shattuck Labs, Inc. still depends on pipeline progress and financing, so the HQ only supports R&D and management, it does not drive stand-alone cash generation.
- Corporate function, not revenue asset
- No recurring cash flow by itself
- Pipeline value still drives economics
Shattuck Labs: No Revenue, No Cash Cow
Shattuck Labs, Inc. is not a Cash Cow in the BCG Matrix. It had 0 approved therapies and $0 product revenue in its latest fiscal reporting, so there is no mature commercial base to harvest.
The Company is still funding R&D and clinical work, so cash burn remains the key story. Until a marketed product creates recurring sales, Shattuck Labs stays in a pre-commercial build phase, not a cash engine.
| Metric | Latest status |
|---|---|
| Approved therapies | 0 |
| Product revenue | $0 |
| BCG fit | Not a Cash Cow |
Full Version Awaits
Shattuck Labs, Inc. Reference Sources
The Shattuck Labs, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No placeholders, no demo content—just the complete, ready-to-use report. Download it instantly and use it for analysis, planning, or presentations. What you preview is what you get.
Dogs
No legacy products
Shattuck Labs, Inc. has no disclosed legacy products, so there is no clear low-share, low-growth cash cow to place in the Dog bucket. The latest filings show no commercial product revenue or mature product line, which keeps this category effectively empty. In BCG terms, that means the portfolio is still centered on pipeline assets, not declining brands.
0 marketed therapies
Shattuck Labs has 0 marketed therapies, so there is no legacy franchise to slip into low-growth decline. Dogs in a BCG Matrix usually come from mature products that have lost relevance; Shattuck is still a development-stage company, not a harvesting story. As of its latest 2025 filings, the revenue base is still tied to R&D, not commercialization.
2 experimental assets
Shattuck Labs, Inc. has 2 experimental assets, and both are still in pre-commercial development, so they do not fit the BCG Dogs label. The main risk is clinical failure, not product obsolescence or weak market share. Until one asset shows durable proof-of-concept and a path to revenue, this is a pipeline risk story, not a mature cash-drain asset story.
Phase 1 only
Both Shattuck Labs, Inc. programs are only in Phase 1, so they are too early for a classic Dog call. Phase 1 assets face very high failure risk, with industry approval odds for oncology drugs often in the low teens, but that is still a pipeline risk stage, not a low-growth mature one.
- Phase 1 means high uncertainty.
- Not yet a mature Dog profile.
- Value depends on later data.
No divestiture asset
Shattuck Labs, Inc. shows no clear divestiture asset in the facts provided. The portfolio is small and early, so there is no obvious dog-like product to sell or shut down. That fits a BCG Dogs view only in the sense of low breadth, not proven weak cash drain.
- No non-core asset is identified.
- Small, early pipeline only.
- No clear sell-off candidate.
No Dogs Here: Shattuck’s Pipeline Is All Risk, No Legacy Drag
Shattuck Labs, Inc. has no marketed products, so the Dogs bucket is effectively empty. As of its latest 2025 filings, it had 0 commercial therapies and 2 Phase 1 assets, which makes this a pipeline-risk story, not a low-share, low-growth legacy drag. There is no clear divestiture target or cash-drain brand to place in Dogs.
| Metric | Data |
|---|---|
| Marketed therapies | 0 |
| Experimental assets | 2 |
| Phase 1 programs | 2 |
Question Marks
SL-172154 Phase 1
SL-172154 is Shattuck Labs, Inc.'s lead experimental drug for ovarian, fallopian tube, and peritoneal cancers. It is still in Phase 1, so market share is 0% today, and the upside is tied to a large unmet need: ovarian cancer caused about 207,000 deaths worldwide in 2022. That makes it a classic Question Mark, with high potential but major clinical and regulatory risk.
SL-279252 Phase 1
SL-279252 Phase 1 is Shattuck Labs, Inc.'s second candidate, now being tested in advanced solid tumors and lymphoma. As a first-in-human, early-stage asset, it has no commercial proof yet, so it fits the BCG Question Mark profile: high potential, but still unproven. The key test is whether early safety and response data can support larger studies and future value creation.
3 gynecologic cancer types
SL-172154 is being tested in ovarian, fallopian tube, and primary peritoneal cancers, three closely linked tumor types that are often grouped in clinical trials. U.S. ovarian cancer alone causes about 19,000 new cases and 12,000 deaths a year, so a positive readout could support a multi-indication label. For now, it is still a Question Mark: high upside, but no proof yet.
2 oncology populations
SL-279252 sits in two oncology populations: advanced solid tumors and lymphoma. The market is broad, but Shattuck Labs, Inc. still lacks clinical proof that the asset can convert that reach into responses, so it stays a Question Mark in the BCG Matrix. In biotech, that usually means heavy follow-on capital is needed before value can mature.
- Broad tumor and lymphoma reach
- Proof of concept still missing
- Needs major R&D funding
0 approved therapies
Shattuck Labs, Inc. stays fully in Question Mark territory because it still has 0 approved therapies, so there is no product revenue to soften R&D risk. Each pipeline asset must clear data gates on its own, and that matters when the company is still funding development without a commercial base. In BCG terms, the whole portfolio needs proof, not promise.
- No approved therapies.
- No commercial cash cushion.
- Pipeline must earn progression.
Shattuck’s Phase 1 Pipeline Still Needs Proof to Escape Question Mark Status
Shattuck Labs, Inc. remains in Question Mark mode because its two main assets, SL-172154 and SL-279252, are still in Phase 1 and have 0 approved therapies behind them. SL-172154 targets ovarian, fallopian tube, and primary peritoneal cancers; SL-279252 targets advanced solid tumors and lymphoma. With no product revenue cushion, each program still needs clear clinical proof to justify more capital.
| Asset | Status | BCG view |
|---|---|---|
| SL-172154 | Phase 1 | Question Mark |
| SL-279252 | Phase 1 | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.